人免疫球蛋白联合神经节苷脂对重症手足口病早期干预的研究

目的研究人免疫球蛋白联合神经节苷脂对重症手足口病早期干预的效果。方法将符合手足口病重症诊断标准的60例患儿随机分为A组和B组,两组均以小剂量甲强龙、降颅压、清热解毒等对症支持治疗。A组除应用常规方法外,同时静脉滴注人免疫球蛋白治疗。B组除运用常规方法外,静脉滴注人免疫球蛋白联合单唾液酸四己糖神经节苷脂治疗。观察两组患儿神经系统功能评分、主要症状及体征恢复时间、平均住院天数等,评价疗效。结果经过治疗两组患儿神经功能评分都有所改善,B组神经功能评分改善更为明显,两组治疗后比较差异有统计学意义（P〈0.05）;主要症状、体征恢复时间B组比A组明显缩短,B组与A组相比住院天数明显缩短,差异均有统计学意（P〈0.05）。结论人免疫球蛋白联合单唾液酸四己糖神经节苷脂治疗HFMD重症在减轻症状,缩短病程,改善神经功能等方面优于单独应用人免疫球蛋白治疗。

The study of treatment effect for initial severe hand-foot mouth disease with IVIG and ganglioside

Objective To study the clinical effect of human intravenous immunoglobulin（IVIG） and ganglioside for initial severe hand-foot-mouth disease（HFMD）.Methods 60 initial severe HFMD patients were divided into Group A and Group B,the two groups are small doses of methylprednisolone,reducing intracranial pressure.A group in addition to the conventional method,IVIG,Group B,in addition to the use of conventional methods,intravenous IVIG and ganglioside.After treatment,observe the nervous system function scores of the two groups of children,the main symptoms,signs of recovery time,the average days of hospi-talization,to evaluate the efficacy.Results After treatment,two groups of children with neurological score have improved.The nerve function scores of B group improved more significantly than group A（P 0.05）;major group B of the symptoms and signs of recovery time is significantly shorter than group A,group B and group A compared length of hospital stay was shortened（P 0.05）.Conclusion The drug combination of HFMD severe in relieve symptoms and shorten the course of the disease,and improve neurological function is superior to IVIG treatment.